Clinical trial
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
NCT01976611 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
- Lead sponsor
- Allergan
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- February 28, 2015
- Enrollment
- 402 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.